Evaluation of HER2 in breast cancer: Reality and expectations

Expert Opinion on Medical Diagnostics

Volumn 3, Issue 6, 2009, Pages 607-620

  Milanezi, Fernanda ^a   Leito, Dina ^a,b   Ricardo, Sara ^a,c   Augusto, Isabel ^d   Schmitt, Fernando ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Breast cancer; HER2; Immunohistochemistry; In situ hybridisation; Target therapy

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; TRASTUZUMAB;

BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; DIAGNOSTIC KIT; DRUG RECEPTOR BINDING; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METASTASIS; ONCOGENE NEU; QUALITY CONTROL; REVIEW;

EID: 77953408795     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530050903222221     Document Type: Review

References (122)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-249
2. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18(3):581-592 (Pubitemid 46359643)
3. Pakkiri P, Lakhani SR, Smart CE. Current and future approach to the pathologist's assessment for targeted therapy in breast cancer. Pathology 2009;41(1):89-99
4. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18(7):1133-1144
5. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19(4):980-991
6. Epstein RJ, Leung TW, Mak J, Cheung PS. Utility of a web-based breast cancer predictive algorithm for adjuvant chemotherapeutic decision making in a multidisciplinary oncology center. Cancer Invest 2006;24(4):367-373
7. Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 2008;14(24):8019-8026
8. Torrisi R, Rotmensz N, Bagnardi V, et al. HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 2007;43(16):2339-2344
9. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: The biology of ErbB-2 and ErbB-3. Exp Cell Res 2003;284(1):54-65
10. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005;5(5):341-354
11. Stern DF. ErbBs in mammary development. Exp Cell Res 2003;284(1):89-98
12. Mosesson Y, Yarden Y. Oncogenic growth factor receptors: Implications for signal transduction therapy. Semin Cancer Biol 2004;14(4):262-270
13. Ramsauer VP, Carraway CA, Salas PJ, Carraway KL. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells. J Biol Chem 2003;278(32):30142-30147
14. Milanezi F, Carvalho S, Schmitt FC. EGFR/HER2 in breast cancer: A biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn 2008;8(4):417-434
15. Holbro T, Beerli RR, Maurer F, et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003;100(15):8933-8938
16. Stern DF. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2008;13(2):215-223
17. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21(14):2787-2799
18. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997;410(1):83-86
19. Daniele L, Sapino A. Anti-HER2 treatment and breast cancer: State of the art, recent patents, and new strategies. Rec Patents Anticancer Drug Discov 2009;4(1):9-18
20. Braga S, dal Lago L, Bernard C, et al. Use of trastuzumab for the treatment of early stage breast cancer. Expert Rev Anticancer Ther 2006;6(8):1153-1164
21. Dowsett M, Hanna WM, Kockx M, et al. Standardization of HER2 testing: Results of an international proficiency-testing ring study. Mod Pathol 2007;20(5):584-591
22. Begon DY, Delacroix L, Vernimmen D, et al. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J Biol Chem 2005;280(26):24428-24434
23. Vernimmen D, Gueders M, Pisvin S, et al. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer 2003;89(5):899-906
24. Citri A, Kochupurakkal BS, Yarden Y. The Achilles heel of ErbB-2/HER2: Regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004;3(1):51-60
25. Citri A, Gan J, Mosesson Y, et al. Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep 2004;5(12):1165-1170
26. Buttitta F, Barassi F, Fresu G, et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 2006;119(11):2586-2591
27. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65(5):1642-1646
28. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177-182
29. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-752
30. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98(19):10869-10874
31. Singer CF, Kostler WJ, Hudelist G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies. Biochim Biophys Acta 2008;1786(2):105-113
32. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25(33):5287-5312 (Pubitemid 350232263)
33. Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 2008;100(1):14-20
34. Dressler LG, Berry DA, Broadwater G, et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005;23(19):4287-4297
35. Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357(15):1496-1506
36. Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005;23(30):7483-7490
37. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8(5):1107-1116
38. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156(3):839-847
39. Di Leo A, Biganzoli L, Claudino W, et al. Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: Ready for the primetime? Eur J Cancer 2008;44(18):2791-2798
40. Orlando L, Del Curto B, Gandini S, et al. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Breast 2008;17(5):506-511
41. Kauraniemi P, Barlund M, Monni O, Kallioniemi A. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res 2001;61(22):8235-8240
42. Vanden Bempt I, Drijkoningen M, De Wolf-Peeters C. The complexity of genotypic alterations underlying HER2-positive breast cancer: An explanation for its clinical heterogeneity. Curr Opin Oncol 2007;19(6):552-557
43. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001;19(18):3808-3816
44. Arimidex T, Forbes JF, Cuzick J, et al.; Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9(1):45-53
45. Dowsett M, Ebbs SR, Dixon JM, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists. J Clin Oncol 2005;23(11):2477-2492
46. Rasmussen BB, Regan MM, Lykkesfeldt AE, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: Supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008;9(1):23-28
47. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: Herceptin and beyond. Eur J Cancer 2008;44(18):2806-2812
48. Molina MA, Saez R, Ramsey EE, et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 2002;8(2):347-353
49. Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991;266(3):1716-1720
50. Saez R, Molina MA, Ramsey EE, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006;12(2):424-431
51. Fornier MN, Seidman AD, Schwartz MK, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: Association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005;16(2):234-239
52. Sandri MT, Johansson H, Colleoni M, et al. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. Anticancer Res 2004;24(2C):1261-1266
53. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-1684
54. Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 2006;11(8):857-867
55. Piccart-Gebhart MJ. Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn. Eur J Cancer 2006;42(12):1715-1719
56. Nielsen DL, Andersson M, Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 2009;35(2):121-136
57. Mariani G, Fasolo A, De Benedictis E, Gianni L. Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 2009;6(2):93-104
58. Tomasello G, de Azambuja E, Dinh P, et al. Jumping higher: Is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther 2008;8(12):1883-1890
59. Molina MA, Codony-Servat J, Albanell J, et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61(12):4744- 4749
60. Nielsen DL, Andersson M, Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 2008, published online 11 November 2008; doi: 10.1016/j.ctrv.2008.09.003
61. Nahta R, Esteva FJ. Herceptin: Mechanisms of action and resistance. Cancer Lett 2006;232(2):123-138
62. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25(1):118-145
63. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13(7):1036-1043
64. Regitnig P, Schippinger W, Lindbauer M, et al. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 2004;203(4):918-926
65. Tapia C, Savic S, Wagner U, et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 2007;9(3):R31
66. Vincent-Salomon A, Jouve M, Genin P, et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002;94(8):2169-2173
67. Gori S, Rimondini S, De Angelis V, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: Incidence, survival, and risk factors. Oncologist 2007;12(7):766-773
68. Duchnowska R, Dziadziuszko R, Czartoryska-Arlukowicz B, et al. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat 2009, published online 7 January 2009; doi: 10.1007/s10549-008-0275-z
69. Park IH, Ro J, Lee KS, et al. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol 2009;20(1):56-62
70. Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009;27(8):1323-1333
71. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244(4905):707- 712
72. Apostolaki S, Perraki M, Pallis A, et al. Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: Evaluation of their clinical relevance. Ann Oncol 2007;18(5):851-858
73. Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: A technical review with interpretive guidelines. Hum Pathol 2005;36(3):250-261
74. Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol 2007;38(8):1105-1122
75. Walker RA, Bartlett JM, Dowsett M, et al. HER2 testing in the UK: Further update to recommendations. J Clin Pathol 2008;61(7):818-824
76. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199(4):418-423
77. Dolan M, Snover D. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am J Clin Pathol 2005;123(5):766-770
78. Bose S, Mohammed M, Shintaku P, Rao PN. Her-2/neu gene amplification in low to moderately expressing breast cancers: Possible role of chromosome 17/Her-2/neu polysomy. Breast J 2001;7(5):337-344
79. + invasive breast cancer: A study of 108 cases comparing ASCO/CAP and FDA recommendations. Mod Pathol 2009;22(3):403-409
80. + weak positive by HercepTest immunohistochemistry: False-positive or false-negative immunohistochemistry? J Clin Pathol 2007;60(6):690-693
81. Mirlacher M, Kasper M, Storz M, et al. Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol 2004;17(11):1414-1420
82. Moeder CB, Giltnane JM, Harigopal M, et al. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: Tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 2007;25(34):5418-5425
83. Vincent-Salomon A, MacGrogan G, Couturier J, et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: Results of the French multicentre GEFPICS study. Histopathology 2003;42(4):337-347
84. Brunelli M, Manfrin E, Martignoni G, et al. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: Impact on selecting patients for herceptin therapy. Am J Clin Pathol 2008;129(6):907-911
85. Ricardo SA, Milanezi F, Carvalho ST, et al. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol 2007;60(9):1001-1005
86. Thor AD, Liu S, Edgerton S, et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer. J Clin Oncol 2000;18(18):3230-3239
87. Hudelist G, Kostler WJ, Attems J, et al. Her-2/neu-triggered intracellular tyrosine kinase activation: In vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer 2003;89(6):983-91
88. DiGiovanna MP, Stern DF, Edgerton SM, et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005;23(6):1152-1160
89. Bussolati G, Montemurro F, Righi L, et al. A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. Br J Cancer 2005;92(7):1261-1267
90. Sapino A, Montemurro F, Marchio C, et al. Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: An hypothesis-generating study. Ann Oncol 2007;18(12):1963-1968
91. Liu PC, Liu X, Li Y, et al. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther 2006;5(6):657-664
92. Esteva FJ, Cheli CD, Fritsche H, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 2005;7(4):R436-43
93. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008;21(Suppl 2):S8-15
94. Hall BH, Ianosi-Irimie M, Javidian P, et al. Computer-assisted assessment of the human epidermal growth factor receptor 2 immunohistochemical assay in imaged histologic sections using a membrane isolation algorithm and quantitative analysis of positive controls. BMC Med Imaging 2008;8:11
95. Gown AM, Goldstein LC, Barry TS, et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol 2008;21(10):1271-1277
96. Cayre A, Mishellany F, Lagarde N, Penault-Llorca F. Comparison of different commercial kits for HER2 testing in breast cancer: Looking for the accurate cutoff for amplification. Breast Cancer Res 2007;9(5):R64
97. Bartlett JM, Campbell FM, Mallon EA. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined? Am J Clin Pathol 2008;130(6):920-926
98. van de Vijver M, Bilous M, Hanna W, et al. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: An international validation ring study. Breast Cancer Res 2007;9(5):R68
99. Kim GY, Oh YL. Chromogenic in situ hybridization analysis of HER-2/neu status in cytological samples of breast carcinoma. Cytopathology 2004;15(6):315-320
100. Isola J, Tanner M, Forsyth A, et al. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004;10(14):4793-4798
101. Lin F, Shen T, Prichard JW. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens. Diagn Cytopathol 2005;33(6):376-380
102. Di Palma S, Collins N, Bilous M, et al. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer. J Clin Pathol 2008;61(6):757-760
103. Laakso M, Tanner M, Isola J. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J Pathol 2006;210(1):3-9
104. Ma YLL, Durbecq V, Paesmans M, et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: Effect on daily practice. Clin Cancer Res 2005;11(12):4393-4399
105. Arnould L, Arveux P, Couturier J, et al. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res 2007;13(21):6404-6409
106. Hofmann M, Stoss O, Gaiser T, et al. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: Assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol 2008;61(1):89-94
107. Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 2007;451(1):19-25
108. Carbone A, Botti G, Gloghini A, et al. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn 2008;10(6):527-536
109. Reddy JC, Reimann JD, Anderson SM, Klein PM. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer 2006;7(2):153-157
110. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24(19):3032-3038
111. O'Malley FP, Thomson T, Julian J, et al. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab. Arch Pathol Lab Med 2008;132(1):61-65
112. Nahta R, Yu D, Hung MC, et al. Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3(5):269-280
113. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12(4):395-402
114. Gori S, Sidoni A, Colozza M, et al. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: Correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol 2009;20(4):648-54
115. Xia W, Husain I, Liu L, et al. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 2007;67(3):1170-1175
116. Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004;23(3):646-653
117. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-2743
118. Blackwell KL, Pegram MD, Tan-Chiu E, et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 2009;20(6):1026-1031, published online 29 january 2009; doi: 10.1093/annonc/mdn759
119. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26(34):5544-52
120. de Azambuja E, Cardoso F, Meirsman L, et al. The new generation of breast cancer clinical trials: The right drug for the right target. Bull Cancer 2008;95(3):352-357
121. Ranieri G, Patruno R, Ruggieri E, et al. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: From the biology to the clinic. Curr Med Chem 2006;13(16):1845-1857
122. + metastatic breast cancer (MBC). J Clin Oncol 2008;26(15 Suppl):abstract 1042